

Meningococcal Vaccines Session

David S. Stephens, M.D.

Chair, Meningococcal Work Group

Advisory Committee on Immunization Practices

June 27, 2019

Serogroup B meningococcal (MenB) booster doses in persons at increased risk for serogroup B meningococcal disease

- ACIP recommends a MenB primary series for persons at increased risk for serogroup B meningococcal disease.
 - Booster doses not currently recommended for persons who remain at increased risk.
- At the February 2019 meeting, data was presented to ACIP on:
 - Persistence of the immune response following MenB primary vaccination
 - Immunogenicity, safety, and persistence of a MenB booster dose
 - Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) and Evidence to Recommendations (EtR) framework for MenB booster doses
 - Work Group interpretation and policy options for MenB booster doses

Meningococcal Vaccines Work Group Activities

- Reviewed ACIP feedback received during the February 2019 meeting.
- Discussed potential programmatic challenges of MenB booster doses.
 - Specific updates proposed to CDC's outbreak guidance related to booster dose implementation during outbreaks.
- Developed an updated ACIP statement to harmonize existing meningococcal vaccine recommendations and potential MenB booster recommendations into a single document.

Agenda

- Summary of immunogenicity and safety data, GRADE, EtR, and policy options for MenB booster doses in persons at increased risk.
 - Sarah Mbaeyi, CDC/NCIRD
- Updated ACIP statement for meningococcal vaccination in the United States.
 - Sarah Mbaeyi, CDC/NCIRD

Votes

- Vote #1: MenB booster doses in persons at increased risk for serogroup B meningococcal disease.
- Vote #2: Updated ACIP meningococcal vaccines statement.

Work Group Members

ACIP Members

- David Stephens (Chair)
- Kelly Moore
- Hank Bernstein
- Veronica McNally

Ex Officio Members

- Lucia Lee (FDA)
- Anuja Rastogi (FDA)
- Ruth Brenner (DOD)

CDC Work Group Lead

- Sarah Mbaeyi (CDC/NCIRD)

Liason Representatives

- Nina Ahmad (AAFP)
- Oliver Baclic (NACI)
- Carol Baker (IDSA)
- Susan Even (ACHA)
- Rachel Herlihy (IAC)
- Nneka Holder (SAHM)
- Martin Luta (CSTE)
- Ruth Lynfield (AAP)
- Paul McKinney (APTR)
- William Schaffner (NFID)

Consultants

- Mike Brady
- Kathleen Harriman
- Mary Healy
- Cody Meissner
- Paul Offit
- Lorry Rubin

CDC contributors

- Alison Albert
- Amy Blain
- Catherine Bozio
- Nicole Brown
- Amanda Cohn
- Jonathan Duffy
- LeAnne Fox
- Rachel Gorwitz
- Susan Hariri
- Angela Jiles
- David Kim
- Andrew Kroger
- Jessica MacNeil
- Lucy McNamara
- Sara Oliver
- Ismael Ortega-Sanchez
- Heather Reese
- Xin Wang
- Lauren Weil
- Charnetta Williams

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

